Equity Details
Price & Market Data
Price: $6.98
Daily Change: +$0.16 / 2.29%
Daily Range: $6.66 - $6.98
Market Cap: $1,968,423,040
Daily Volume: 1,636,803
Performance Metrics
1 Week: -1.30%
1 Month: 54.98%
3 Months: 52.90%
6 Months: 78.85%
1 Year: 195.3%
YTD: 24.55%
About Taysha Gene Therapies, Inc. (TSHA)
Essential market details for Taysha Gene Therapies, Inc. (TSHA). Current price: 6.98, daily change: +$0.16 / 2.29%. Market cap: 1,968,423,040. Dive into YTD, 1-week, and 6-month performance.
Company Details
Employees: 99
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.